PRESS RELEASE published on 06/20/2024 at 07:30, 2 years 1 month ago Inside Information / Other news releases GenSight Biologics renegotiates financial obligations and provides operational updates, with successful capital increases enhancing short-term flexibility Financial Obligations Operational Updates GenSight Biologics Capital Increases Gene Therapies
BRIEF published on 06/04/2024 at 07:35, 2 years 2 months ago GenSight Biologics to Present at Key Medical Conferences in 2024 Gene Therapy GenSight Biologics Medical Conferences 2024 LUMEVOQ® LHON
BRIEF published on 06/04/2024 at 07:35, 2 years 2 months ago GenSight Biologics fera une présentation lors de conférences médicales clés en 2024 Thérapie Génique Produits Biologiques GenSight LUMEVOQ® Conférences Médicales 2024 NOHL
PRESS RELEASE published on 06/04/2024 at 07:30, 2 years 2 months ago Inside Information / Other news releases GenSight Biologics to present at key medical and stakeholder meetings, including 16th Meeting of the EUNOS. Papers on LUMEVOQ® for LHON to be showcased Gene Therapy GenSight Biologics Medical Conferences LUMEVOQ Retinal Neurodegenerative Diseases
PRESS RELEASE published on 06/04/2024 at 07:30, 2 years 2 months ago Informations privilégiées / Autres communiqués GenSight Biologics va présenter ses thérapies géniques innovantes pour les maladies neurodégénératives lors de conférences médicales et scientifiques importantes Thérapie Génique GenSight Biologics Maladies Neurodégénératives Conférences Médicales Présentations Scientifiques
BRIEF published on 06/03/2024 at 07:35, 2 years 2 months ago GenSight Biologics accueille William Monteith au Conseil d’administration Conseil D’administration Nomination GenSight Biologics Thérapies Géniques William Monteith
BRIEF published on 06/03/2024 at 07:35, 2 years 2 months ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 2 months ago Informations privilégiées / Autres communiqués GenSight Biologics nomme William Monteith à son Conseil d'administration. Monteith apportera son expertise en fabrication de thérapies géniques pour soutenir les progrès de l'entreprise Conseil D'administration Fabrication GenSight Biologics Thérapies Géniques William Monteith
BRIEF published on 05/23/2024 at 11:40, 2 years 2 months ago Franchissement de seuils pour GENSIGHT BIOLOGICS S.A. Actions Franchissement De Seuils Bons De Souscription GenSight Biologics Armistice Capital
BRIEF published on 05/23/2024 at 11:40, 2 years 2 months ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
Published on 08/15/2026 at 00:50, 16 hours 33 minutes ago Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 17 hours 8 minutes ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 17 hours 38 minutes ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 17 hours 58 minutes ago NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 18 hours 23 minutes ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/15/2026 at 15:05, 2 hours 18 minutes ago Brook Gaming Officially Launches Sniper 2 Flagship Keyboard and Mouse Converter for Cross-Platform Console Gaming
Published on 08/15/2026 at 08:05, 9 hours 18 minutes ago SKYWORTH Solar to Launch SolaMate Balcony Solar System on Joybuy Germany on August 15
Published on 08/14/2026 at 18:15, 23 hours 8 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/13/2026 at 18:00, 1 day 23 hours ago Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 23 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 23 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 23 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 23 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
